JCR Pharmaceuticals

Name

JCR Pharmaceuticals

Legal name

JCR Pharmaceuticals Co., Ltd.

Website

https://jcrpharm.co.jp

Company type

Public

Founded year

1976

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Specialty Biopharmaceuticals (Rare Disease Biologics)

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industries

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Rare disease therapeutics
• Biologics manufacturing
• Blood-brain barrier delivery
• Gene therapy platforms
• Specialty pharmaceuticals

Headquarters

HQ city

Hyogo

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: JCR generates revenue from sales of approved pharmaceutical products including IZCARGO® (pabinafusp alfa/IZCARGO) for mucopolysaccharidosis type II in Japan, with global clinical trials ongoing for JR-141 and other pipeline products.
2. Licensing Milestone Payments: JCR receives development and sales milestone payments from licensing partnerships. Notable deals include up to USD 555 million from Acumen Pharmaceuticals for Alzheimer's disease candidates using J-Brain Cargo® technology, and up to USD 825 million from Alexion (AstraZeneca) for JUST-AAV capsid platform.
3. Royalty Revenue: Post-commercialization, JCR receives tiered royalties on net sales from licensees including tiered royalties from Acumen and other partners.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

JCR Pharmaceuticals is an integrated Japanese biopharmaceutical company that develops, manufactures, and commercializes rare disease therapeutics built on two proprietary platforms: J-Brain Cargo® (a transferrin-receptor-targeting blood-brain barrier penetration technology) and JUST-AAV (an engineered AAV gene therapy platform). Its commercial product IZCARGO® (pabinafusp alfa) for mucopolysaccharidosis type II was approved in Japan in 2021 as the world's first clinically applied BBB-penetrating biologic, and the company monetizes its platforms both through direct product sales and high-value global out-licensing deals.

Product overview

JCR Pharmaceuticals is a Japanese biotech company operating as a global specialty pharma focused on neurodegenerative and rare diseases. The company's product portfolio centers on two proprietary platform technologies: J-Brain Cargo®, a blood-brain barrier penetration technology enabling CNS drug delivery, and JUST-AAV, an engineered AAV-based gene therapy platform. The commercial product IZCARGO® (pabinafusp alfa/JR-141) for MPS II leverages J-Brain Cargo® and was approved in Japan in 2021 as the world's first clinically applied BBB-penetrating therapy. The clinical pipeline includes JR-171 (lepunafusp alfa) for MPS I and JR-471 for fucosidosis. Strategic partnerships with Acumen Pharmaceuticals (Alzheimer's), Alexion/AstraZeneca (gene therapy capsids), and Italfarmaco (givinostat for DMD) extend the platforms into additional therapeutic areas.

Differentiator

Problem solved

Functional benefit

Products and services

• J-Brain Cargo® Proprietary blood-brain barrier (BBB) penetration technology platform that enables drug delivery to the brain and spinal cord by targeting transferrin receptors on brain vascular endothelial cells. Applicable across enzymes, antibodies, oligonucleotides, lipid nanoparticles, gene therapies, and cell therapies. Licensed to global pharmaceutical partners for use in CNS-targeted therapeutic programs.
• JUST-AAV Proprietary engineered adeno-associated virus (AAV) gene therapy platform enabling efficient gene delivery to target tissues or organs while reducing off-target distribution. Includes liver-detargeted, muscle-targeted, and brain-targeted capsid variants with modified surface tags (binders or miniaturized antibodies) for tissue-specific targeting.
• IZCARGO® (pabinafusp alfa / JR-141) Enzyme replacement therapy for mucopolysaccharidosis type II (MPS II / Hunter syndrome) that uses J-Brain Cargo® technology to cross the blood-brain barrier and deliver IDS enzyme to both systemic and CNS tissues via transferrin receptor-mediated delivery. Approved and commercially available in Japan; supplied abroad through named-patient programs via Clinigen Limited.
• JR-171 (lepunafusp alfa) Investigational enzyme replacement therapy for mucopolysaccharidosis type I (MPS I) combining α-L-iduronidase with J-Brain Cargo® technology to target both peripheral and CNS symptoms via mannose-6-phosphate receptor-mediated action plus transferrin receptor-mediated BBB crossing. Received FDA Fast Track Designation.
• JR-471 Investigational therapy for fucosidosis developed in partnership with MEDIPAL HOLDINGS CORPORATION utilizing J-Brain Cargo® technology. Preclinical data showed more than 95% substrate reduction and preserved motor function in murine models.
• ACU301 and ACU401 (Acumen Enhanced Brain Delivery candidates) Alzheimer's disease development candidates combining Acumen's AβO-selective antibody expertise with JCR's J-Brain Cargo® BBB-penetration technology, achieving 14-40x higher brain penetration in non-human primates compared to native antibodies. Developed under license from JCR with up to USD 555M in potential milestone payments plus tiered royalties.

Quantifiable outcome

• 14-40x higher brain penetration in non-human primates compared to native antibodies (Acumen EBD program)
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Acumen PharmaceuticalscoreStrategic or Co-development Partner · 17 June 2026Acumen Pharmaceuticals exercised its exclusive option to develop, manufacture, and commercialize up to two therapeutic candidates for Alzheimer's disease using JCR's proprietary J-Brain Cargo® blood-brain barrier technology platform. JCR is eligible to receive up to USD 555 million in development and sales milestone payments, plus tiered royalties on net sales. Acumen plans to file an IND application in mid-2027.
• SanBio Co., Ltd.minorImplementation/ SI/ Consulting Partner · 22 April 2026Manufacturing agreement where JCR Pharma produces AKUUGO (regenerative medicine product) for SanBio, indicating JCR's contract manufacturing capabilities for cell therapy products.
• Italfarmaco S.p.A.minorStrategic or Co-development Partner · 24 December 2025Exclusive licensing agreement for the development and commercialization of givinostat in Japan, focusing on Duchenne muscular dystrophy (DMD). Also includes strategic collaboration to explore joint opportunities for treating rare diseases and expand access to givinostat and future innovations.
• Alexion (AstraZeneca Rare Disease)coreStrategic or Co-development Partner · 9 July 2025License agreement granting Alexion access to JCR's proprietary JUST-AAV capsid platform for use in up to five of Alexion's genomic medicine programs. JCR is eligible to receive upfront payment plus milestone payments totaling up to USD 825 million (approximately JPY 120 billion), including up to USD 225 million for R&D and up to USD 600 million for sales milestones, along with tiered royalties on net sales. This is the third partnership between JCR and Alexion.
• Clinigen LimitedminorChannel Partner/ Reseller/ Distributor · 1 March 2023Named Patient Supply program agreement for IZCARGO® to provide access to the drug in countries where it has not yet been approved, enabling patients who meet medical needs, regulations, and standards of each country to access treatment.
• MEDIPAL HOLDINGS CORPORATIONcoreStrategic or Co-development PartnerBusiness and capital alliance with MEDIPAL HOLDINGS CORPORATION, which holds 23.86% of JCR's outstanding shares. Partnership includes multiple development investment contracts. MEDIPAL is a major Japanese pharmaceutical wholesale company.
• Angelini PharmaminorStrategic or Co-development PartnerAngelini Industries (parent of Angelini Pharma) has partnerships including agreements with Sovargen, GRIN Therapeutics, and JCR Pharmaceuticals as part of Brain Health expansion strategy.
• Fujifilm Cellular DynamicsminorOthersListed as a major company in the Japan cell therapy market alongside JCR Pharmaceuticals, though specific partnership details not detailed in available sources.
• MEDIPAL HOLDINGS CORPORATION (JR-471 partnership)minorStrategic or Co-development PartnerJR-471 for fucosidosis developed in partnership with MEDIPAL HOLDINGS CORPORATION, representing one of multiple LSD indications in JCR's pipeline.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Denali Therapeutics: Denali is the most direct peer to JCR in blood-brain barrier delivery technology, developing enzyme and antibody transport vehicle (ATV) platforms for neurodegenerative and lysosomal storage diseases. Both companies are pursuing transferrin-receptor-mediated CNS delivery of biologics for LSDs and neurodegeneration.
• BioMarin Pharmaceutical: BioMarin is a leading rare-disease specialty pharma with approved enzyme replacement therapies (e.g., for MPS I, IVA, VI) directly overlapping JCR's IZCARGO and JR-171 franchises. Both companies target the same LSD patient populations with biologic therapies, making BioMarin the dominant commercial benchmark in JCR's core market.
• Ultragenyx Pharmaceutical: Ultragenyx is a rare-disease biotech with both biologic and gene therapy programs targeting LSDs and metabolic disorders — directly overlapping JCR's J-Brain Cargo LSD pipeline. Both companies pursue cross-modality rare-disease strategies (enzymes, gene therapy) and compete for the same patients in MPS I/II and other LSDs.
• Voyager Therapeutics: Voyager develops engineered AAV capsid platforms (including TRACER-derived CNS-targeted capsids) for gene therapy — directly comparable to JCR's JUST-AAV platform. Both companies monetize proprietary AAV capsid IP via licensing to large pharma and pursue CNS-directed gene therapies.
• REGENXBIO: REGENXBIO is a leading AAV gene therapy platform company (NAV Technology) that licenses its capsids to multiple partners — a comparable platform-monetization model to JCR's JUST-AAV. Both companies develop proprietary AAV capsids for CNS, ocular, and other indications and generate revenue through licensing milestones and royalties.
• Sarepta Therapeutics: Sarepta is a gene therapy specialist with approved AAV-based therapies (Elevidys for DMD) and active programs in CNS and muscular dystrophy — overlapping JCR's JUST-AAV platform applications and rare-disease focus. Both companies develop AAV-delivered biologics for neuromuscular and CNS indications.

Emerging players

• Passage Bio: Passage Bio is an early-stage CNS gene therapy company developing AAV-delivered therapies for rare neurological diseases — a partial overlap with JCR's JUST-AAV and J-Brain Cargo combined applications. Smaller and more narrowly focused than JCR, but competes for similar BBB/gene-therapy positioning.

Broad incumbents

• Takeda Pharmaceutical: Takeda is Japan's largest pharmaceutical company and a global leader in rare diseases (post-Shire acquisition), with overlapping LSD and rare disease franchises. As a broad incumbent, Takeda competes with JCR in Japan specialty pharma and could be a potential acquirer or licensor of JCR's platforms.
• Astellas Pharma: Astellas is a major Japanese pharmaceutical company with growing rare-disease and gene therapy ambitions (acquisition of Audentes). It competes broadly with JCR in Japan specialty pharma and is developing its own AAV gene therapy programs that could overlap with JUST-AAV applications.
• Genentech (Roche): Roche/Genentech is a global leader in CNS drug development with multiple BBB-penetrating programs and a large Alzheimer's/neurodegenerative pipeline. As a broad incumbent, Roche competes with JCR's J-Brain Cargo in CNS biologics delivery and represents both a competitor and a potential licensing partner.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/jcr-pharmaceuticals-co-ltd

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about JCR Pharmaceuticals